LEA (Letrozol/Fulvestrant and Avastin)
Introduction - LEA
Multicenter, randomized study to evaluate the efficacy and safety of Bevacizumab in combination with endocrine treatment compared to endocrine treatment alone, in postmenopausal women with advanced or metastatic breast cancer with indication of hormontherapy as first-line treatment
Design - LEA
Multicenter, randomized study to evaluate the efficacy and safety of Bevacizumab in combination with endocrine treatment compared to endocrine treatment alone, in postmenopausal women with advanced or metastatic breast cancer with indication of hormontherapy as first-line treatment
Documents - LEA
Important trial specific documents are available for download here.
Contact - LEA
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Fax: 06102 / 7480-440
GEICAM-Trial: English Summary - LEA
Multicenter, randomized study to evaluate the efficacy and safety of Bevacizumab in combination with endocrine treatment compared to endocrine treatment alone, in postmenopausal women with advanced or metastatic breast cancer with indication of hormontherapy as first-line treatmentCurrent Status: recruiting completed